This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AZD3480
Description: AZD3480 is an orally active, selective, partial agonist of the central a4ß2 neuronal nicotinic acetylcholine receptor (nAChR). Studies have shown a reduced number of a4ß2 nAChRs in persons with dementia, suggesting the involvement of a4ß2 in cognition. In preclinical animal studies, AZD3480 triggered activity of a4ß2, enhanced the release of acetylcholine, enhanced memory and showed meaningful separation between the doses at which positive effects on memory and side effects were first seen. In two preclinical in vitro studies, AZD3480 protected neuronal cells from deterioration and death, a process known as neuroprotection.
Deal Structure: In December 2005, Targacept and AstraZeneca announced that they have entered into an exclusive global license and research collaboration agreement for the development and commercialization of TC-1734 to treat cognitive disorders. Targacept is eligible to receive up to approximately $300 million in payments, together with stepped double digit royalties dependent on sales achieved following regulatory approval.
AstraZeneca will be primarily responsible for and will fund the development and commercialization of TC-1734 and any compounds that arise out of the four-year research collaboration. Targacept has retained an option to co-promote TC-1734 and any compounds discovered in the research collaboration in the United States.
In March 2013, AstraZeneca and Targacept restructured their agreement. AstraZeneca will return to Targacept all rights to the alpha4beta2 modulator TC-1734 (AZD3480).
Targacept and Catalyst
In March 2015, Targacept and Catalyst Biosciences...See full deal structure in Biomedtracker
Additional information available to subscribers only: